3 May 2023
\n \n \n \nThe European Medicines Agency (EMA) initiative DARWIN EU\u00ae has completed its first studies and is calling for new data partners
\n \n\n \n \n5 April 2023
\n \n \n \nA study to monitor the safety and effectiveness of the COVID-19 vaccine in the Global South, has received funding from the Bill & Melinda Gates Foundation\u2019s Grand Challenges initiative.
\n \n\n \n \n3 April 2023
\n \n \n \nAssociate Professor Jonathan Cook has been elected to the Society for Clinical Trials (SCT) board.
\n \n\n \n \n17 March 2023
\n \n \n \nCongratulations to Eileen Morrow and Mae Chester-Jones who have received NIHR Doctoral Fellowships
\n \n\n \n \n7 March 2023
\n \n \n \nThe Oxford Clinical Trials Research Unit (OCTRU) has received NIHR benchmarking results and offers excellent value for money according to the report
\n \n\n \n \n9 February 2023
\n \n \n \nThe newly developed model to estimate the health benefits and budget impact of Fracture Liaison Services (FLS) finds them highly effective in shaping positive patient outcomes, and will help drive policy decisions.
\n \n\n \n \n28 October 2022
\n \n \n \nResearchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.
\n \n\n \n \n19 August 2022
\n \n \n \nResearchers at NDORMS have studied the association between ambulatory COVID-19 and short-term risk of venal thrombosis and the clinical and genetic risk factors predisposing them to developing post\u2013COVID-19 thrombosis.
\n \n\n \n \n21 July 2022
\n \n \n \nWorking with researchers across multiple universities, the Oxford Clinical Trials Unit (OCTRU) played a key role in delivering results of the national VROOM trial (Vaccine Response On Off Methotrexate).
\n \n\n \n \n14 May 2022
\n \n \n \nA recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.
\n \n\n \n \n14 March 2022
\n \n \n \nA new collaboration between Oxford, Brazil and Pakistan has been funded by the Bill & Melinda Gates Foundation. The partnership will provide researchers with de-identified health data from two of the worlds global COVID-19 hotspots to increase understanding of COVID-19 in these communities and help accelerate the management of the disease.
\n \n\n \n \n11 February 2022
\n \n \n \nThe European Medicines Agency has announced the establishment of the Data Analysis and Real World Interrogation Network (DARWIN EU\u00ae) to support better decision making on the development and effectiveness of medicines and vaccines.
\n \n\n \n \n25 November 2021
\n \n \n \nA new study shows that a vaccine surveillance method in observational data may generate high number of false positives
\n \n\n \n \n11 November 2021
\n \n \n \nNDORMS is leading one of nine new studies awarded total of \u00a32m to use large-scale linked data to address priority research questions that will improve understanding of the pandemic and inform the continued policy response.
\n \n\n \n \n22 October 2021
\n \n \n \nA new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.
\n \n\n \n \n21 September 2021
\n \n \n \nResearchers at NDORMS have developed a new set of guidelines for reporting mediation analyses in health research.
\n \n\n \n \n18 August 2021
\n \n \n \nA new collaborative study between the Catalan Institute of Health, the Public Health Secreatariat of Catalonia, and the Centre for Statistics in Medicine, NDORMS, at the University of Oxford have confirmed that COVID-19 vaccines greatly reduce infections, hospitalisations and mortality for up to 6 months.
\n \n\n \n \n14 June 2021
\n \n \n \nThe largest, most extensive global network study on background rates for adverse events of special interest identifies important age, sex and database differences that should inform future safety surveillance efforts.
\n \n\n \n \n11 June 2021
\n \n \n \nDani Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology at NDORMS, has been elected as the Academic representative for Europe and Africa on the International Society of Pharmaco-Epidemiology Board of Directors.
\n \n\n \n \n11 May 2021
\n \n \n \nInsufficient data, and misleading recommendations led to significant early heterogeneity in global COVID-19 patient management, according to recent BMJ study
\n \n\n \n \n